New platform to accelerate drug discovery in Taiwan

Nuclera, the biotechnology company providing rapid access to functional proteins for drug discovery, has completed its first installations in Asia. Systems are now operational at the National Taiwan University College of Medicine and National Cheng Kung University, marking Nuclera’s first commercial sales in the region.

Purchased and donated by Show Chung Ho, President of YFY Academy and Founder of E Ink Holdings, the systems will support collaborative protein drug discovery research. NTU and NCKU will use the platform for early-stage screening of peptide and protein drug candidates, as well as protein microarrays for clinical research applications.

“eProtein Discovery accelerates protein production workflows by rapidly identifying optimal expression and purification conditions,” said Michael Chen, CEO and co-founder of Nuclera. “These installations strengthen our global footprint and support pioneering research in protein therapeutics.”

Combining cell-free expression systems, digital microfluidics, and screening data, the platform helps researchers select the most promising proteins early, reducing time, cost, and uncertainty in protein expression and purification.

Nuclera is represented in Taiwan by Unimed Healthcare Inc, providing local distribution and support.

More information online